Avastin licence extended in metastatic breast cancer

Bevacizumab is also licensed for colorectal, lung and renal cancer
Bevacizumab is also licensed for colorectal, lung and renal cancer
The licensed use of bevacizumab (Avastin) for the treatment of metastatic breast cancer has been broadened to include use in combination with capecitabine when taxanes or anthracyclines are not appropriate. Patients who have received taxane and anthracycline-containing regimens should not receive bevacizumab in combination with capecitabine.

Use of bevacizumab with capecitabine was evaluated in the multicentre, placebo-controlled, phase 3 RIBBON-1 study in patients with HER2-negative metastatic or locally recurrent breast cancer. Patients (n=1237) were randomised to receive chemotherapy plus bevacizumab or chemotherapy plus placebo every 3 weeks. Chemotherapy options included capecitabine, a taxane and anthracycline-based agents.

For statistical analysis, patients were divided into 2 cohorts defined by chemotherapy received. The primary endpoint, median progression-free survival, was longer for capecitabine plus bevacizumab than for capecitabine plus placebo: 8.6 months vs 5.7 months, with a hazard ratio of 0.69 (95% CI 0.56-0.84; p<0.001).

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Calcium and Vitamin D Supplements for Osteoporosis

Calcium and Vitamin D Supplements for Osteoporosis

Formulations, doses and costs of osteoporosis supplements.

Asthma and COPD Preparations and Compatible Devices

Asthma and COPD Preparations and Compatible Devices

Available presentations of bronchodilators and anti-inflammatories.

Topical Steroids, Comparison of Potencies and Formulations

Topical Steroids, Comparison of Potencies and Formulations

Strengths and formulations of topical steroids.

Topical Steroids, Potential Skin Sensitisers as Ingredients

Topical Steroids, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in topical steroids.